Nurix Therapeutics Inc. (NRIX): Price and Financial Metrics
GET POWR RATINGS... FREE!
NRIX POWR Grades
- NRIX scores best on the Value dimension, with a Value rank ahead of 62.91% of US stocks.
- The strongest trend for NRIX is in Growth, which has been heading down over the past 160 days.
- NRIX ranks lowest in Momentum; there it ranks in the 4th percentile.
NRIX Stock Summary
- NRIX's went public 1.49 years ago, making it older than merely 2.41% of listed US stocks we're tracking.
- For NRIX, its debt to operating expenses ratio is greater than that reported by just 0.39% of US equities we're observing.
- With a price/sales ratio of 30.55, Nurix Therapeutics Inc has a higher such ratio than 94.24% of stocks in our set.
- Stocks that are quantitatively similar to NRIX, based on their financial statements, market capitalization, and price volatility, are PTGX, SGMO, XENE, JNCE, and GLYC.
- NRIX's SEC filings can be seen here. And to visit Nurix Therapeutics Inc's official web site, go to www.nurixtx.com.
NRIX Valuation Summary
- In comparison to the median Healthcare stock, NRIX's price/earnings ratio is 144.11% lower, now standing at -16.1.
- Over the past 13 months, NRIX's price/earnings ratio has gone up 16.3.
- NRIX's price/earnings ratio has moved up 16.3 over the prior 13 months.
Below are key valuation metrics over time for NRIX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NRIX | 2021-08-31 | 62.5 | 3.6 | -16.1 | -14.0 |
| NRIX | 2021-08-30 | 64.9 | 3.7 | -16.7 | -14.6 |
| NRIX | 2021-08-27 | 62.4 | 3.6 | -16.0 | -14.0 |
| NRIX | 2021-08-26 | 60.4 | 3.5 | -15.5 | -13.4 |
| NRIX | 2021-08-25 | 59.6 | 3.4 | -15.3 | -13.2 |
| NRIX | 2021-08-24 | 60.5 | 3.5 | -15.5 | -13.5 |
NRIX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NRIX has a Quality Grade of D, ranking ahead of 10.83% of graded US stocks.
- NRIX's asset turnover comes in at 0.064 -- ranking 303rd of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows NRIX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-08-31 | 0.064 | 1 | -0.385 |
| 2021-05-31 | 0.053 | 1 | -0.422 |
| 2020-11-30 | 0.081 | 1 | -0.566 |
NRIX Price Target
For more insight on analysts targets of NRIX, see our NRIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $49.17 | Average Broker Recommendation | 1.36 (Strong Buy) |
NRIX Stock Price Chart Interactive Chart >
NRIX Price/Volume Stats
| Current price | $19.49 | 52-week high | $51.46 |
| Prev. close | $19.89 | 52-week low | $19.14 |
| Day low | $19.14 | Volume | 523,400 |
| Day high | $20.33 | Avg. volume | 402,917 |
| 50-day MA | $28.89 | Dividend yield | N/A |
| 200-day MA | $29.81 | Market Cap | 869.51M |
Nurix Therapeutics Inc. (NRIX) Company Bio
Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Latest NRIX News From Around the Web
Below are the latest news stories about Nurix Therapeutics Inc that investors may wish to consider to help them evaluate NRIX as an investment opportunity.
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 CatalystsNurix leads protein modulation field with four active clinical stage programs Anticipates data-rich 2022 with clinical-stage programs and a pipeline fueled by proprietary DELigase platform SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today outlined key objectives and anticipated milestones for 2022 and provided an overview of recent progress. “2021 was a significant and highly p |
Nurix Therapeutics (NRIX) Gets a Buy Rating from NeedhamNeedham analyst Gil Blum reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $48.00. The company's shares closed last Tuesday at $28.84. According to TipRanks.com, Blum has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -25.0% and a 16.4% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Rocket Pharmaceuticals. Nurix Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $55.17, representing an 83.7% upside. In a report issued on December 29, H.C. |
2 “Strong Buy” Stocks Primed for 2022 GainsWall Street traders have no shortage of cliches, and here’s a happy thought for the New Year: ‘So goes January, so goes the year.’ Sam Stovall, chief investment strategist from CFRA Research, has taken note of this quirk, writing: “If the market does well in the month of January, then it usually does well for the full year. But if we find that a lot of money has flowed into the markets, right off the bat, then the indication is that it's likely to be a very good year.” Talking of sentiment, the |
Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare ConferenceSAN FRANCISCO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix will present an overview of corporate performance in 2021 and major goals for 2022 at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 5:15 pm ET. The presentation will be webcast live and may be accessed v |
Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual MeetingU.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022 NX‑5948 crosses the blood‑brain barrier in preclinical models enabling potential dual development in oncology and autoimmune diseases of the central nervous system NX‑5948 reduces tumor burden and extends survival in a preclinical model of primary central nervous system lymphoma SAN FRANCISCO, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), |
NRIX Price Returns
| 1-mo | -30.39% |
| 3-mo | -30.79% |
| 6-mo | -36.56% |
| 1-year | -61.15% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -32.68% |
| 2021 | -11.95% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...